Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer

A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette–Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Med Oncol
Main Authors: Liem, Esmee I. M. L., Baard, Joyce, Cauberg, Evelyne C. C., Bus, Mieke T. J., de Bruin, D. Martijn, Laguna Pes, M. Pilar, de la Rosette, Jean J. M. C. H., de Reijke, Theo M.
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer US 2017
נושאים:
Original Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581817/
https://ncbi.nlm.nih.gov/pubmed/28866819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-1033-z
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים